Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of[...]
Regeneron Pharmaceuticals Inc.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of[...]
Title and Summary Summary ToggleSynaptics Incorporated Prices $400.0[...]
11/05/2024 | Press release | Archived content
Please select the service you want to use:
Smartlinks | Banc of California Inc. | News | Crime and Judiciary | Judiciary | Finance | Security Markets | Security Markets | Company News | Corporate Debt | Financial Services | Banking | Judiciary | Securities Issuers | Banks | New York Stock Exchange (NYSE) | Frankfurt Stock Exchange | Berlin Stock Exchange | Dusseldorf Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Tradegate Exchange | NYSE American | NYSE ARCA Equities | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | Investors Exchange (IEX) | Nasdaq BX | Nasdaq Intermarket | Nasdaq PSX | NYSE Chicago
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact